Study drug QTX3034 for patients with KRAS G12D solid tumors (QTX3034-001) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to see if the study drug, QTX3034, either with or without cetuximab, is safe and effective for treating KRAS G12D mutated cancer. We are also trying to find the best dose of QTX3034 to use.
What is the Condition Being Studied?
Solid Tumors with KRAS G12D Mutation
Who Can Participate in the Study?
Adults with solid tumors that:
- Are locally advanced or metastatic
- Contain a KRAS G12D mutation
- Have worsened following at least 1 line of standard therapy
For more information about this study, please contact the study team at 919-668-1861.
Age Group
Adults
What is Involved?
If you choose to join this study, you will:
- Take the study drug, QTX3034, by mouth twice every day
- Depending on which group you are assigned to, you may also get IV infusions of cetuximab once every week
- Have your tumor biopsied
- Give blood and urine samples
- Have regular CT or MRI scans
Study Details
Full Title
[QTX3034-001] A Phase 1 Trial evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients with Solid Tumors with KRASG12D mutation
Principal Investigator
Medical Oncologist
Protocol Number
IRB:
PRO00114908
NCT:
NCT06227377
Phase
Phase
I
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Call 919-668-1861
or email gi-oncology-cru@dm.duke.edu